AZD0305
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
What will happen during the trial?
This study will follow a modular protocol design evaluating AZD0305 as monotherapy and in combination with other anticancer agents. The protocol may be amended in the future to incorporate further monotherapy expansion at the recommended Phase 2 dose (RP2D) in Phase II, and/or additional modules investigating AZD0305 in combination with other anticancer agents.
The study consists of 3 modules:
- Module 1 (AZD0305 monotherapy)
- Module 2 (AZD0305 in combination with elranatamab)
- Module 3 (AZD0305 in combination with pomalidomide and dexamethasone [Pd])
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 226 patients (estimated)
- Sponsors
- AstraZeneca
- Tags
- Antibody Drug Conjugate (ADC), GPRC5D
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1787
- NCT Identifier
- NCT06106945
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.